Literature DB >> 7870934

The discriminative stimulus properties of buspirone involve dopamine-2 receptor antagonist activity.

H J Rijnders1, J L Slangen.   

Abstract

To investigate a dopaminergic component in the discriminative stimulus properties of buspirone, rats were trained to discriminate 2.5 mg/kg buspirone from saline, using a two lever, food-rewarded, fixed ratio 10 operant procedure. To test the dopamine-2 (D2) antagonist action of buspirone, a second group of rats was trained to discriminate 0.16 mg/kg apomorphine from saline. In addition to a complete generalization to 8-OH-DPAT, the D2 antagonists haloperidol, R 79598 and sulpiride showed a partial generalization to buspirone. The benzodiazepine ligands chlordiazepoxide and bretazenil did not generalize to the buspirone cue. Buspirone (2.0 mg/kg) completely blocked the apomorphine cue in the apomorphine trained rats. Haloperidol, R 79895 and sulpiride also blocked the apomorphine cue, although at doses much smaller than the doses needed to evoke buspirone responding in the buspirone trained group. 8-OH-DPAT did not antagonize apomorphine. It was concluded that the D2 action of buspirone partially contributes to its discriminative stimulus properties. Mediation of the buspirone cue by 5-HT1a receptor activation seemed predominant. Further, buspirone can act as a full D2 antagonist in drug discrimination. A model was proposed suggesting a compound discriminative stimulus complex of buspirone with a dominant 5-HT1a component that overshadows a less pronounced D2 component.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7870934     DOI: 10.1007/bf02257407

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  28 in total

1.  Extinction and reacquisition of differential responding in rats trained to discriminate between chlordiazepoxide and saline.

Authors:  H J Rijnders; T U Järbe; J L Slangen
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

2.  Discriminative stimulus properties of flesinoxan.

Authors:  C E Ybema; J L Slangen; B Olivier; J Mos
Journal:  Pharmacol Biochem Behav       Date:  1990-04       Impact factor: 3.533

3.  Behavioral differentiation of the stimulus properties of a dopaminergic D1 agonist from a D2 agonist.

Authors:  D A Cory-Slechta; D V Widzowski; M C Newland
Journal:  J Pharmacol Exp Ther       Date:  1989-09       Impact factor: 4.030

4.  Buspirone blocks the discriminative stimulus effects of apomorphine in monkeys.

Authors:  J B Kamien; W L Woolverton
Journal:  Pharmacol Biochem Behav       Date:  1990-01       Impact factor: 3.533

5.  SCH 23390--a selective dopamine D-1 receptor antagonist with putative 5-HT1 receptor agonistic activity.

Authors:  T Skarsfeldt; J J Larsen
Journal:  Eur J Pharmacol       Date:  1988-04-13       Impact factor: 4.432

6.  Behavioral studies with anxiolytic drugs. VI. Effects on punished responding of drugs interacting with serotonin receptor subtypes.

Authors:  S Gleeson; S T Ahlers; R S Mansbach; J M Foust; J E Barrett
Journal:  J Pharmacol Exp Ther       Date:  1989-09       Impact factor: 4.030

7.  Anticonflict effects of the 5-HT1A compound flesinoxan.

Authors:  J E Barrett; S Gleeson; M A Nader; S M Hoffmann
Journal:  J Psychopharmacol       Date:  1989-01       Impact factor: 4.153

8.  Further characterization of the discriminative stimulus effects of buspirone using monoamine agonists and antagonists in the pigeon.

Authors:  M.A. Nader; S. Hoffmann; S. Gleeson; J.E. Barrett
Journal:  Behav Pharmacol       Date:  1989       Impact factor: 2.293

9.  Behavioral effects of D1 and D2 dopamine receptor antagonists in squirrel monkeys.

Authors:  J Bergman; B K Madras; R D Spealman
Journal:  J Pharmacol Exp Ther       Date:  1991-09       Impact factor: 4.030

10.  Discriminative stimulus properties of D1 and D2 dopamine agonists in rats.

Authors:  J B Kamien; L I Goldberg; W L Woolverton
Journal:  J Pharmacol Exp Ther       Date:  1987-09       Impact factor: 4.030

View more
  7 in total

Review 1.  Advances in non-nicotine pharmacotherapy for smoking cessation.

Authors:  L S Covey; M A Sullivan; J A Johnston; A H Glassman; M D Robinson; D P Adams
Journal:  Drugs       Date:  2000-01       Impact factor: 9.546

2.  The anxiolytic CRF(1) antagonist DMP696 fails to function as a discriminative stimulus and does not substitute for chlordiazepoxide in rats.

Authors:  Snjezana Lelas; Kim L Zeller; Kathryn A Ward; John F McElroy
Journal:  Psychopharmacology (Berl)       Date:  2003-02-18       Impact factor: 4.530

3.  Discriminative stimulus properties of the 5-HT1A receptor biased agonists NLX-101 and F13714, in rats trained to discriminate 8-OH-DPAT from saline.

Authors:  Jillian H Broadbear; Ronan Y Depoortere; Kristina Vacy; David Ralph; Brendan J Tunstall; Adrian Newman-Tancredi
Journal:  Behav Pharmacol       Date:  2021-12-01       Impact factor: 2.293

4.  Effects of chronic buspirone treatment on cocaine self-administration.

Authors:  Nancy K Mello; Peter A Fivel; Stephen J Kohut; Jack Bergman
Journal:  Neuropsychopharmacology       Date:  2012-10-17       Impact factor: 7.853

5.  Efficacy of buspirone for attenuating cocaine and methamphetamine reinstatement in rats.

Authors:  Keith L Shelton; Elizabeth S Hendrick; Patrick M Beardsley
Journal:  Drug Alcohol Depend       Date:  2013-01-29       Impact factor: 4.492

6.  Role of Serotonin Neurons in L-DOPA- and Graft-Induced Dyskinesia in a Rat Model of Parkinson's Disease.

Authors:  Eunju Shin; Elisabetta Tronci; Manolo Carta
Journal:  Parkinsons Dis       Date:  2012-06-11

Review 7.  Foetal Cell Transplantation for Parkinson's Disease: Focus on Graft-Induced Dyskinesia.

Authors:  Elisabetta Tronci; Camino Fidalgo; Manolo Carta
Journal:  Parkinsons Dis       Date:  2015-12-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.